Literature DB >> 28740064

Successful combination immunotherapy of anti-gamma aminobutyric acid (GABA)A receptor antibody-positive encephalitis with extensive multifocal brain lesions.

Yuki Fukami1, Hiroaki Okada1, Mari Yoshida2, Keiji Yamaguchi1.   

Abstract

A 78-year old woman who presented with akinetic mutism was admitted to our hospital. Brain MRI showed multifocal increased T2/FLAIR signal with extensive cortical-subcortical involvement. We suspected autoimmune encephalitis and the patient received methylprednisolone pulse. Her conscious level gradually recovered, but later relapsed again and presented with refractory status epilepticus. We treated her with intravenous immunoglobulin, plasma exchange and pulsed cyclophosphamide, with satisfactory response. A brain biopsy showed perivascular lymphocytic infiltrates and reactive gliosis. Anti-gamma aminobutyric acid (GABA)A receptor antibodies test came back to be positive after her recovery, and the diagnosis of anti-GABAA receptor antibody-positive encephalitis was made. This is a very rare case where brain biopsies were performed in a patient with anti-GABAA receptor antibody-positive encephalitis.

Entities:  

Keywords:  anti-gamma aminobutyric acid (GABA)A receptor antibody; autoimmune encephalitis; refractory status epilepticus

Mesh:

Substances:

Year:  2017        PMID: 28740064     DOI: 10.5692/clinicalneurol.cn-001038

Source DB:  PubMed          Journal:  Rinsho Shinkeigaku        ISSN: 0009-918X


  2 in total

Review 1.  Autoimmune Encephalitis in Children: From Suspicion to Diagnosis.

Authors:  Kam Lun Ellis Hon; Alexander K Leung; Cheuk Chung Au; Alcy R Torres
Journal:  Cureus       Date:  2021-02-12

2.  Immunotherapy-responsive Non-paraneoplastic Encephalitis with Antibodies against GAD, LGI1, and GABAA Receptor.

Authors:  Takahiro Nakano; Norio Chihara; Kento Matoba; Hisatsugu Tachibana; Shiho Okuda; Yoshihisa Otsuka; Takehiro Ueda; Kenji Sekiguchi; Hisatomo Kowa; Frank Leypoldt; Klaus-Peter Wandinger; Riki Matsumoto
Journal:  Intern Med       Date:  2021-07-30       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.